As of 31 July 2023, the National Clinical Evidence Taskforce is no longer funded. The COVID-19 and MPX guidelines are still accessible online, but are not currently being updated.
For more information and the latest developments in Australian living evidence visit livingevidence.org.au
The National Clinical Evidence Taskforce (the Taskforce) aims to support Australia’s healthcare professionals caring for people with urgent and emerging diseases, by providing continually updated, evidence-based clinical guidelines.
We bring together 35-member organisations to undertake continuous evidence surveillance to identify and rapidly synthesise emerging research in order to provide national, evidence-based guidelines.
These are ‘living’ guidelines, updated as new research emerges in order to give reliable, up-to-date advice to clinicians providing frontline care for people with these illnesses.
Australia is a world-leader in the development of living guidelines through the work of the Australian Living Evidence Consortium and in partnership with Cochrane Australia, the world’s most trusted provider of health evidence.
Each week the Taskforce identifies, evaluates and synthesises evidence to be used as the basis of new recommendations for the clinical care of people with urgent and emerging diseases (currently, COVID-19 and MPX). The Taskforce also identifies and includes any new research evidence that might influence our existing recommendations. Our clinical experts meet as required to review the evidence and make new and updated recommendations, which are endorsed by our Taskforce members and immediately published online.
We move quickly, and value your input and suggestions as we continue to revise, expand and improve our guidelines.
The National Clinical Evidence Taskforce is funded by:
Previous serving members:
Previous serving members:
The Australian Living Evidence Consortium (ALEC) was established in 2018 to support and develop ‘Living’ evidence and guidelines – an approach that enables almost real time updating of the latest research and guidance without compromising the rigorous, gold standard methods needed to provide trustworthy recommendations. The initial focus areas were stroke, diabetes, arthritis and kidney disease.
In response to the COVID-19 pandemic in early 2020, ALEC pivoted its development program to create the National COVID-19 Clinical Evidence Taskforce.
As the pandemic continued, the Taskforce established its own governance structure and funding model and in 2021 the Taskforce became the 13th member of ALEC.
The Taskforce joined ALEC’s inaugural member organisations:
ALEC is pursuing funding support from Commonwealth, State and Territory governments and is generously supported by the following philanthropic organisations: